Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: Efficacy of second-generation tyrosine kinase inhibitors

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1144-1146

  Nand, Ranveer ^a   Bryke, Christine ^b   Kroft, Steven H ^a   Divgi, Ajit ^c   Bredeson, Christopher ^a   Atallah, Ehab ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Comprehensive Genetic Services SC ^*  (United States)

^c Oncology Alliance   (United States)

Author keywords

Chronic myeloproliferative disorders; ETV6 ABL gene rearrangement; Second generation tyrosine kinase inhibitors; Tyrosinke kinase inhibitors

Indexed keywords

ABELSON KINASE; DASATINIB; IMATINIB; JANUS KINASE 2; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR ETV6;

ADULT; ARTICLE; BACKACHE; BLAST CELL CRISIS; BLOOD CELL COUNT; BONE MARROW BIOPSY; BRONCHITIS; BRUISING; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL EVALUATION; CLINICAL FEATURE; CYTOGENETICS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; EOSINOPHILIA; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL HEMORRHAGE; GENE REARRANGEMENT; HIP PAIN; HUMAN; KARYOTYPING; MONOTHERAPY; MOUTH ULCER; MYELOPROLIFERATIVE DISORDER; NIGHT SWEAT; ONCOGENE; PANCYTOPENIA; PERIORBITAL EDEMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RELAPSE; REMISSION; SPLENOMEGALY; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EOSINOPHILIA; FEMALE; GENE REARRANGEMENT; HUMANS; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REMISSION INDUCTION;

EID: 67349165083     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.011     Document Type: Article

References (25)

1. Tefferi A., and Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22 (2008) 14-22
2. Andreasson P., Johansson B., Carlsson M., Jarlsfelt I., Fioretos T., Mitelman F., et al. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Gene Chromosome Canc 20 (1997) 299-304
3. Golub T.R., Goga A., Barker G.F., Afar D.E., McLaughlin J., Bohlander S.K., et al. Oligomerization of the ABL tyrosine kinase by the ETS protein TEL in human leukemia. Mol Cell Biol 16 (1996) 4107-4116
4. Nilsson T., Andreasson P., Hoglund M., Fioretos T., Billstrom R., Garwicz S., et al. ETV6/ABL fusion is rare in Ph-negative chronic myeloid disorders. Leukemia 12 (1998) 1167-1168
5. Papadopoulos P., Ridge S.A., Boucher C.A., Stocking C., and Wiedemann L.M. The novel activation of ABL by fusion to an ETS-related gene, TEL. Cancer Res 55 (1995) 34-38
6. Tirado C.A., Sebastian S., Moore J.O., Gong J.Z., and Goodman B.K. Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. Cancer Genet Cytogenet 157 (2005) 74-77
7. Van Limbergen H., Beverloo H.B., van Drunen E., Janssens A., Hahlen K., Poppe B., et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Gene Chromosome Canc 30 (2001) 274-282
8. Keung Y.K., Beaty M., Steward W., Jackle B., and Pettnati M. Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet 138 (2002) 139-142
9. Janssen J.W., Ridge S.A., Papadopoulos P., Cotter F., Ludwig W.D., Fonatsch C., et al. The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event. Br J Haematol 90 (1995) 222-224
10. Keene P., Mendelow B., Pinto M.R., Bezwoda W., MacDougall L., Falkson G., et al. Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association. Br J Haematol 67 (1987) 25-31
11. Yahata N., Ohyashiki K., Ohyashiki J.H., Kimura Y., Miyazawa K., Kodama A., et al. Late appearance of t(5;12)(q31;p12) in acute myeloid leukemia associated with eosinophilia. Cancer Genet Cytogenet 107 (1998) 147-150
12. David M., Cross N.C., Burgstaller S., Chase A., Curtis C., Dang R., et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 109 (2007) 61-64
13. Berkowicz M., Rechavi G., Rosner E., Ben-Bassat I., and Ramot B. Involvement of both chromosomes 5 in a patient with leukemia secondary to myelodysplastic syndrome. Cancer Genet Cytogenet 48 (1990) 279-280
14. Jani K., Kempski H.M., and Reeves B.R. A case of myelodysplasia with eosinophilia having a translocation t(5;12) (q31;q13) restricted to myeloid cells but not involving eosinophils. Br J Haematol 87 (1994) 57-60
15. Srivastava A., Boswell H.S., Heerema N.A., Nahreini P., Lauer R.C., Antony A.C., et al. KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. Cancer Genet Cytogenet 35 (1988) 61-71
16. Baranger L., Szapiro N., Gardais J., Hillion J., Derre J., Francois S., et al. Translocation t(5;12)(q31-q33;p12-p13): a non-random translocation associated with a myeloid disorder with eosinophilia. Br J Haematol 88 (1994) 343-347
17. Wessels J.W., Fibbe W.E., van der Keur D., Landegent J.E., van der Plas D.C., den Ottolander G.J., et al. t(5;12)(q31;p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia. Cancer Genet Cytogenet 65 (1993) 7-11
18. Okuda K., Golub T.R., Gilliland D.G., and Griffin J.D. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 13 (1996) 1147-1152
19. Voss J., Posern G., Hannemann J.R., Wiedemann L.M., Turhan A.G., Poirel H., et al. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. Oncogene 19 (2000) 1684-1690
20. Kawamata N., Dashti A., Lu D., Miller B., Koeffler H.P., Schreck R., et al. Chronic phase of ETV6-ABL1 positive CML responds to imatinib. Gene Chromosome Canc 47 (2008) 919-921
21. Million R.P., Aster J., Gilliland D.G., and Van Etten R.A. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood 99 (2002) 4568-4577
22. O'Brien S.G., Vieira S.A., Connors S., Bown N., Chang J., Capdeville R., et al. Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood 99 (2002) 3465-3467
23. Pellier I., Le Moine P.J., Rialland X., Francois S., Baranger L., Blanchet O., et al. Myelodysplastic syndrome with t(5;12)(q31;p12-p13) and eosinophilia: a pediatric case with review of literature. J Pediatr Hematol Oncol 18 (1996) 285-288
24. Hochhaus A., Baccarani M., Deininger M., Apperley J.F., Lipton J.H., Goldberg S.L., et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22 (2008) 1200-1206
25. Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2007) 3540-3546